PURPOSE: We compared diagnostic ability for detecting hepatic metastases between gadolinium ethoxy benzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) on a 1.5-T system, and determined whether DWI is necessary in Gd-EOB-DTPA-enhanced MRI for diagnosing colorectal liver metastases. MATERIALS AND METHODS: We assessed 29 consecutive prospectively enrolled patients with suspected metachronous colorectal liver metastases; all patients underwent surgery and had preoperative Gd-EOB-DTPA-enhanced MRI. Overall detection rate, sensitivity for detecting metastases and benign lesions, positive predictive value, and diagnostic accuracy (Az value) were compared among three image sets [unenhanced MRI (DWI set), Gd-EOB-DTPA-enhanced MRI excluding DWI (EOB set), and combined set]. RESULTS: Gd-EOB-DTPA-enhanced MRI yielded better overall detection rate (77.8-79.0 %) and sensitivity (87.1-89.4 %) for detecting metastases than the DWI set (55.9 % and 64.7 %, respectively) for one observer (P < 0.001). No statistically significant difference was seen between the EOB and combined sets, although several metastases were newly detected on additional DWI. CONCLUSIONS: Gd-EOB-DTPA-enhanced MRI yielded a better overall detection rate and higher sensitivity for detecting metastases compared with unenhanced MRI. Additional DWI may be able to reduce oversight of lesions in Gd-EOB-DTPA-enhanced 1.5-T MRI for detecting colorectal liver metastases.
PURPOSE: We compared diagnostic ability for detecting hepatic metastases between gadolinium ethoxy benzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) and diffusion-weighted imaging (DWI) on a 1.5-T system, and determined whether DWI is necessary in Gd-EOB-DTPA-enhanced MRI for diagnosing colorectal liver metastases. MATERIALS AND METHODS: We assessed 29 consecutive prospectively enrolled patients with suspected metachronous colorectal liver metastases; all patients underwent surgery and had preoperative Gd-EOB-DTPA-enhanced MRI. Overall detection rate, sensitivity for detecting metastases and benign lesions, positive predictive value, and diagnostic accuracy (Az value) were compared among three image sets [unenhanced MRI (DWI set), Gd-EOB-DTPA-enhanced MRI excluding DWI (EOB set), and combined set]. RESULTS:Gd-EOB-DTPA-enhanced MRI yielded better overall detection rate (77.8-79.0 %) and sensitivity (87.1-89.4 %) for detecting metastases than the DWI set (55.9 % and 64.7 %, respectively) for one observer (P < 0.001). No statistically significant difference was seen between the EOB and combined sets, although several metastases were newly detected on additional DWI. CONCLUSIONS:Gd-EOB-DTPA-enhanced MRI yielded a better overall detection rate and higher sensitivity for detecting metastases compared with unenhanced MRI. Additional DWI may be able to reduce oversight of lesions in Gd-EOB-DTPA-enhanced 1.5-T MRI for detecting colorectal liver metastases.
Authors: Alexander Huppertz; Thomas Balzer; Anthony Blakeborough; Josy Breuer; Andrea Giovagnoni; Gertraud Heinz-Peer; Michael Laniado; Riccardo M Manfredi; Didier G Mathieu; Dieter Mueller; Peter Reimer; Philip J Robinson; Michael Strotzer; Matthias Taupitz; Thomas J Vogl Journal: Radiology Date: 2004-01 Impact factor: 11.105
Authors: Andrew S Kennedy; David S Ball; Steven J Cohen; Michael Cohn; Douglas M Coldwell; Alain Drooz; Eduardo Ehrenwald; Samir Kanani; Charles W Nutting; Fred M Moeslein; Samuel G Putnam; Steven C Rose; Michael A Savin; Sabine Schirm; Navesh K Sharma; Eric A Wang Journal: J Gastrointest Oncol Date: 2015-12
Authors: Elmar M Merkle; Christoph J Zech; Carlo Bartolozzi; Mustafa R Bashir; Ahmed Ba-Ssalamah; Alexander Huppertz; Jeong Min Lee; Jens Ricke; Michiie Sakamoto; Claude B Sirlin; Sheng-Long Ye; Mengsu Zeng Journal: Eur Radiol Date: 2015-06-13 Impact factor: 5.315
Authors: C Verhoef; M G Besselink; J Stoker; B Görgec; I Hansen; G Kemmerich; T Syversveen; M Abu Hilal; E J T Belt; R H C Bisschops; T L Bollen; K Bosscha; M C Burgmans; V Cappendijk; M T De Boer; M D'Hondt; B Edwin; H Gielkens; D J Grünhagen; P Gillardin; P D Gobardhan; H H Hartgrink; K Horsthuis; N F M Kok; P A M Kint; J W H Kruimer; W K G Leclercq; D J Lips; B Lutin; M Maas; H A Marsman; M Morone; J P Pennings; J Peringa; W W Te Riele; M Vermaas; D Wicherts; F E J A Willemssen; B M Zonderhuis; P M M Bossuyt; R J Swijnenburg; Å A Fretland Journal: BMC Cancer Date: 2021-10-18 Impact factor: 4.430